Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| eptacog alfa (activated) | Drug |
| ||
| Feiba VH | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison with FEIBA on review of pain, joint mobility and circumference | after 1, 3, 6, and 9 hours of treatment, respectively |
| Measure | Description | Time Frame |
|---|---|---|
| Safety variables |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Registry (GCR, 1452) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational Site | Little Rock | Arkansas | 72202 | United States | ||
| Novo Nordisk Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18081834 | Result | Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008 Mar;14(2):287-94. doi: 10.1111/j.1365-2516.2007.01601.x. Epub 2007 Dec 10. |
| Label | URL |
|---|---|
| Clinical Trials at Novo Nordisk | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Berkeley |
| California |
| 94704 |
| United States |
| Novo Nordisk Investigational Site | Los Angeles | California | 90027 | United States |
| Novo Nordisk Investigational Site | Aurora | Colorado | 80010 | United States |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60612 | United States |
| Novo Nordisk Investigational Site | Indianapolis | Indiana | 46260 | United States |
| Novo Nordisk Investigational Site | Iowa City | Iowa | 52242 | United States |
| Novo Nordisk Investigational Site | New Orleans | Louisiana | 70112 | United States |
| Novo Nordisk Investigational Site | Boston | Massachusetts | 02115 | United States |
| Novo Nordisk Investigational Site | Detroit | Michigan | 48201 | United States |
| Novo Nordisk Investigational Site | Minneapolis | Minnesota | 55404 | United States |
| Novo Nordisk Investigational Site | New Brunswick | New Jersey | 08903 | United States |
| Novo Nordisk Investigational Site | Newark | New Jersey | 07112 | United States |
| Novo Nordisk Investigational Site | New York | New York | 10029-6574 | United States |
| Novo Nordisk Investigational Site | Chapel Hill | North Carolina | 27599-7220 | United States |
| Novo Nordisk Investigational Site | Cincinnati | Ohio | 45229 | United States |
| Novo Nordisk Investigational Site | Hershey | Pennsylvania | 17033 | United States |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19104 | United States |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19134-1095 | United States |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | United States |
| ID | Term |
|---|---|
| D005167 | Factor VII |
| C065655 | anti-inhibitor coagulant complex |
| ID | Term |
|---|---|
| D004792 | Enzyme Precursors |
| D045762 | Enzymes and Coenzymes |
| D001779 | Blood Coagulation Factors |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011498 | Protein Precursors |
| D001685 | Biological Factors |
Not provided
Not provided